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Abstract
The role of probiotics in potential prophylaxis of infectious disease 
has been studied for over a century, but until recently there has been 
no real interest in using these ‘benign’ bacterial species in place of or 
in combination with antibiotics. However, such suggestions are now 
commonplace and lead to a renewed interest in what has until recently 
been seen as a merely commercial branch of microbiology. This short 
review looks at the current literature in this area and attempts to 
identify if there is a scientific basis to inform the cautious clinical use 
of probiotics either alone or in combination with antibiotics. Whilst the 
evidence base is to date rather thin, there is sufficient to allow for a 
cautious support for such ideas. This review also identifies those areas 
in which further study is required before the general use of probiotics 
in the treatment of infection may be fully supported.
Introduction
Since the discovery of antibiotics less attention has been paid to older 
and more traditional treatments, such as probiotics [1]. Antibiotics, 
which were once considered to be “miracle drugs”, are now losing 
their effectiveness, particularly due to the overuse and misuse of an-
tibiotics and subsequently to the increasing development of antibiotic 
resistance [1]. With each cycle of antibiotic-use the risk of recurrence 
due to resistance development increases by up to 60%, which is why 
alternative solutions are needed [2]. This has all led to the need for 
an alternative and safe long-term solution for the treatment of some 
infectious diseases [1]. Could probiotics be the solution to these prob-
lems and an effective alternative ? Several recent studies and clinical 
trials have exhibited potential significant benefits of probiotics in the 
prevention and treatment of infectious diseases. Probiotics also have 
the additional benefit of being generally considered as safe, with very 
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few side effects. It is the aim of this brief review 
to investigate current opinion on the potential role 
of probiotics in the treatment of infectious disease 
and to attempt to identify the relationship between 
probiotics and antibiotics in clinical situations.
The history and resurgence of probiotics
Probiotics are not a new concept and their health 
benefits and clinical uses have been studied for many 
years [3]. Modern research on this topic began in 
1908, when Eli Metchnikoff won the Nobel Prize 
for medicine for his work on immunology, which 
included studies on the role of probiotics in human 
health and longevity [3]. Metchnikoff was the first 
scientist to suggest that consuming certain bacteria 
found in sour milk and dairy products (used on the 
Eurasian steppe)could help replace harmful bacteria 
in the body and lead to increased longevity [3, 4]. 
In recent years the number of such products avail-
able has increased, as well as the modern con-
sumer’s familiarity with their proposed benefits 
and subsequently, this has generated much scien-
tific research into the topic [5]. In 2006, over 600 
commercial products were available using the term 
‘probiotic [5]. ‘Probiotic’ is a conflation of the Latin 
and Greek words “pro”and “bios”, which together 
mean ‘for life” [6]. A modern definition of the term 
includes “ probiotic drugs, probiotic food products 
(foods, food ingredients and dietary supplements), 
direct-fed microbials (probiotics for animal use) and 
designer probiotics (genetically modified probiot-
ics)” [7]. Probiotics are most commonly marketed 
as foods or dietary supplements [7]. 
Probiotics can be defined as “live microorganisms 
which, when consumed in adequate amounts, con-
fer a health benefit on the host beyond basic nu-
trition” [5, 8-10]. Lactobacilli are some of the most 
widely used probiotic microorganisms [11]. Probiotic 
strains which have been studied most extensively in-
clude Lactobacillus GG and Saccharomyces boulardii 
[3]. Probiotic food is defined as “a processed food 
product which contains viable probiotic organisms 
in a suitable matrix and sufficient concentration” [5]. 
Lactic acid bacteria (LAB) can be found in fruit, veg-
etables and fermented food products. LAB are also 
present in the gastrointestinal tract and urogenital 
system of humans and animals [12] Probiotics are 
also commonly found in dietary supplements, milks, 
yogurts, powders and pills [3].
Probiotics and human health
According to Gomes da Cruz et al. [5], “count-
less benefits to health are provided by the inges-
tion of foods containing probiotic cultures, some 
with scientific proof and other ones still needing 
more human studies”. Several ways have been sug-
gested by which probiotics enhance human health.
Various studies [6, 13, 14]. provide evidence of the 
benefits that probiotic formulations have with ref-
erence to the immune system, skin and allergies, 
surgical practice, urogenital infections, GI diseases 
such as diverticulitis, irritable bowel syndrome (IBS) 
and irritable bowel disease (IBD), Helicobacter py-
lori eradication, diarrhoea and carcinogenesis. One 
of the areas in which probiotics have received the 
most attention is in the prevention and treatment of 
various gastrointestinal diseases, including IBD, IBS, 
antibiotic-associated diarrhoea (AAD) and dysbiosis 
[15-17]. The overuse of vaccination and antibiotics 
has also been linked to dysbiosis [6]. Dysbiosis is said 
to occur when the normal profile of GI bacterial mi-
croflora becomes altered, which subsequently leads 
to an imbalance in the metabolic or immunological 
feedback of the host, possible rheumatoid arthritis 
and ankylosing spondylitis [6]. The use of probiotics 
has been investigated in the prevention and man-
agement of a wide range of infectious diseases, 
in particular infections of the GI tract. In a review 
conducted by Wolvers et al. [18], the following con-
ditions were mentioned as possible side-effects of 
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GI microfloral imbalance: “1. infectious diarrhoea in 
infants and children, 2. traveller’s diarrhoea, 3. nec-
rotizing enterocolitis in infants, 4. Helicobacter py-
lori infection, 5. respiratory tract infections in adults 
and children and ear, nose and throat infections.”
Probiotics are also considered as useful in the treat-
ment of post-operative infectious complications and 
infections in immuno-compromised patients [18]. 
Although most studies lack conclusive evidence and 
consistency, significant evidence has been found to 
support the use of probiotics in managing infectious 
diarrhoea in children, traveller’s diarrhoea (TD), an-
tibiotic-associated diarrhoea (AAD) and necrotizing 
enterocolitis (NEC) [18]. NEC is particularly common 
in pre-term infants, in comparison with healthy, 
full-term infants[18]. A study by Caplan et al. [18]. 
found that enteral administration of probiotics in 
pre-term infants could have significant benefits in 
reducing the risk of NEC and also reducing the as-
sociated use of antibiotics. Pre-term infants are of-
ten treated in intensive care units, receiving various 
broad spectrum antibiotics and this contributes to 
alterations in gastrointestinal tract colonization pat-
terns[18]. It has been suggested that these altera-
tions in pre-term infants play an important role in 
the pathogenesis of NEC and form a subsequent 
risk of increased infection [18]. However, in order for 
probiotic supplementation to become routine prac-
tice in the prevention of NEC in pre-term infants, 
it has been suggested that these results need to 
be validated by large, well-designed clinical trials in 
order to provide evidence for the efficacy and safety 
of probiotics in the prevention of NEC in pre-term 
infants [18]. 
Helicobacter pylori has been confirmed as a major 
cause of peptic ulcer disease and chronic gastric 
disease, as well as a contributing factor to the de-
velopment of stomach cancer[18]. There are several 
difficulties involved in the eradication of H. pylori, 
which includes the rapid rate at which bacteria de-
velop resistance to drugs and the unwanted side-
effects that are associated with the use of these 
drugs, which subsequently increases the need for 
an effective alternative treatment [20-21]. Probiotics 
have been found to be effective in the eradication 
of H. pylori when used as an adjunct to antibiotic 
therapy and also, in reducing the undesirable side-
effects associated with antibiotic therapy itself [18]. 
One of the most common medical concerns, par-
ticularly in women, are urogenital infections [6]. The 
most common urogenital complaints in women in-
clude recurrent urinary tract infections, which are 
most commonly caused by E. coli, recurrent bacte-
rial vaginosis (BV) caused by Gardnerella vaginalis 
and also recurrent yeast vaginosis normally caused 
by Candida albicans [6]. However, lactobacilli have 
been shown to be the most predominant bacteria 
in the urinary tract of healthy females [18]. Usually 
these types of infections are treated with antibiotics 
and although they are generally effective, there is 
also a high incidence of recurrence [22]. Probiotics 
have been suggested as an alternative to antibiotic 
therapy for the treatment and prevention of uro-
genital infections, particularly since probiotics are 
effective in competing with pathogens for uroepi-
thelial adhesion sites. They also produce substances 
that inhibit pathogen growth and secrete antimicro-
bial biosurfactants [6,23]. Another successful study 
by Anukam et al. [24]. showed that L. rhamnosus 
GR-1 and L. reuteri RC-14 were more effective than 
metronidazole treatment for bacterial vaginosis (BV) 
and this finding was reported as the first effective 
(90%) cure for BV [6]. It has also been reported 
that combinations of various probiotic strains may 
enhance or complement the health benefits that 
an individual strain exhibits [9]. The beneficial char-
acteristics exhibited in one strain, when used in a 
combination with other probiotic strains, could have 
an effect on the mechanisms by which they inhibit 
or displace pathogens and compete for nutrients 
[9]. Current data supports the hypothesis that us-
THE INTERNATIONAL ARABIC JOURNAL 
OF ANTIMICROBIAL AGENTS
2014
Vol. 4 No. 1:5
doi: 10.3823/747
This article is available from: www.iajaa.org4 Received 18 August 2014; accepted 22 August 2014
ing combinations of probiotics or probiotics with 
antibiotics could have major health benefits and this 
topic needs to be further researched [9]. It has been 
suggested that “Probiotic combinations that inhibit 
and displace pathogens may be good candidates 
in case of specific microbiota aberrancies related to 
disease risk reduction” [9]. Results also indicate that 
when probiotic strains are used in combination with 
other probiotics and with antibiotics, this has an 
impact on pathogen adhesion properties, including 
inhibition, displacement and competition [9]. The 
study and control of such effects would be useful 
for the development of new probiotic combinations 
for treating specific diseases by preventing the ad-
hesion of specific pathogens and have a massive 
impact on the disease [9]. However, the effects of 
health improvement depend on the strains present 
in the product and, so far, no probiotic strains have 
been shown to provide the complete range of the 
health benefits reported [5, 25]. Although several 
clinical trials have reported significant health ben-
efits of probiotics, further trials are needed involving 
larger numbers of patients in order to provide con-
clusive evidence of their preventative and curative 
role in medical practice [6]. 
The safety of Probiotics
Although probiotics are generally considered safe 
[1, 6]. There have been reports of probiotic-related 
fungaemia and bacteraemia in severely immuno-
compromised patients [26, 27]. It has also been 
questioned as to whether they are safe for use in 
patients with severe inflammatory gut conditions 
and hence, this is a topic that requires further in-
vestigation [2]. Normally the safety assessment of 
dietary supplements is undertaken post-marketing 
[7] and the safety of probiotics is often assessed 
using animal models [28]. It is important for health 
care practitioners to have a clear understanding on 
the various uses of probiotics, as well as dosages 
and safety aspects in order to better educate pa-
tients and their families on the health benefits of 
probiotics [3]. Screening for specific probiotic strains 
will also allow the identification of strains without 
any potential oral health hazards [29]. Some studies 
have shown a risk of fungaemia in immunocom-
promised patients associated with Saccharomyces 
boulardii [1 ]. Other studies have shown that the risk 
of developing septicaemia in immunocompromised 
patients and of endocarditis in patients with dam-
aged or artificial heart valves increases after their 
being treated with lactobacilli [1]. 
If a probiotic is to be considered for use in hospital-
ized patients, it has to be carefully assessed and the 
risks versus benefits should be carefully assessed [7] 
It is also important that probiotics are administered 
safely in order to ensure patient safety [7]. In ad-
dition to these reports it has been suggested that 
clinical studies on the use of probiotics fail to record 
any adverse effects of probiotics and their overall 
tolerability in patients [30]. There is also a lack of 
data on the long-term safety of probiotics, since 
most trials on the safety of probiotics are only of 
short duration [30]. Therefore, in a small proportion 
of patients, such as those with acute or co-morbid 
conditions or in hospitalized patients, the use of 
probiotics might not be suitable as a treatment 
regime [7, 30]. It has been suggested that more 
appropriately designed studies of sufficient dura-
tion are needed in order to determine the safety 
aspects and tolerability of probiotics [30]. However, 
Snydman reported in an article called ‘The Safety 
of Probiotics’,various concerns regarding their safety 
[31]. The first is the occurrence of disease due to 
bacteraemia, endocarditis and sepsis; secondly there 
is a possibility of toxic or metabolic effects on the 
gastrointestinal tract by probiotics [6]. The third con-
cern that Snydman reported was the possibility of 
transfer of antibiotic resistance from probiotic spe-
cies to potential pathogens in the GI flora [31]. How-
ever, cases of probiotic-related bacteraemia are very 
rare, with most epidemiological surveys suggesting 
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that probiotics can be used safely in most clinical 
situations [6]. LAB have a GRAS-status (generally 
recognised as safe) and because of their health ben-
efits as probiotics they have been widely researched 
[12]. In comparison to pharmaceutical agents they 
are generally regarded as safer, with less serious ad-
verse side effects. However, in certain circumstances 
probiotic microorganisms can be infective and cause 
adverse health effects, for example in malnourished 
or immunosuppressed patients [32]. There have also 
been cases of bacteraemia following the intake of 
Lactobacillus rhamnosus GG in patients with under-
lying diseases [28]. According to Venugopalanet al. 
[7] the reporting of adverse events associated with 
the use of probiotics is very important to determine 
whether they are safe to be used in other than 
healthy populations. 
 In order to be an effective treatment for various 
infectious diseases, especially gastrointestinal in-
fections, probiotics must be non-pathogenic and 
must act against pathogens by mechanisms differ-
ing from those of antibiotics, for example by com-
petition[1]. Other essential qualities are that they 
have a rapid onset of action, are able to survive in 
the gastrointestinal tract and related environmental 
challenges (eg: the presence of bile salts, gastric 
acid and antibiotics) and also potentially modify 
the host’s immune system in order to destroy the 
invading pathogen [1]. Hart et al. [33] suggested 
that probiotics need to be viable in order to dem-
onstrate their beneficial effects. However, some 
studies have shown that even non-viable probiotic 
bacteria might have similar beneficial effects, as 
live probiotic strains. However, it is probably the 
case that probiotics must be viable at the time of 
consumption in order to achieve maximum health 
benefits. Many conventional types of lactobacilli are 
often inactivated by bile or low pH [6]. In order to be 
effective and considered a good probiotic, it has to 
meet the following requirements: “1. being able to 
adhere to cells; 2. excluding or reducing pathogenic 
adherence; 3. being able to persist, multiply and 
produce acid, hydrogen peroxide and bacteriocins 
antagonistic to pathogen growth; 4. being able to 
be safe, non-invasive, non-carcinogenic and non-
pathogenic; 5. being able to congregate as to form 
a normal balanced flora” [6]. 
Probiotics versus Antibiotics in the 
prevention and treatment of infectious 
diseases 
According to D’Souza et al. the “increasing avail-
ability, lower costs and relative lack of side effects 
of probiotics contrasts with the problems associated 
with current antibiotic regimens.” Probiotic micro-
organisms that have been isolated and studiedto 
date include Streptococcus thermophilus, Lactoba-
cillus bulgaricus, Bifodobacterium spp., B. longum, 
Enterococcus faecium, Saccharomyces boulardii, L. 
acidophilus, L. casei and Lactobacillus GG [1]. Some 
of the advantages of probiotic microorganisms, such 
as S. boulardii,over antibiotics include: being read-
ily available, easy to administer and cost-effective 
when compared to antibiotics such as vancomycin 
[1]. The use of broad spectrum antibiotics has also 
been associated with several side effects, including 
disruption of the normal human microflora, lead-
ing to bacterial overgrowth and infections such as 
yeast vaginitis [22]. A common side effect associ-
ated with the long-term use of antibiotics is anti-
biotic-associated diarrhoea (AAD) [1,18]. AAD has 
been defined as “otherwise unexplained diarrhoea 
occurring in association with antibiotic administra-
tion” and it has been estimated that the incidence 
AAD in the paediatric population is between 11 and 
40% between the initiation of antibiotic therapy 
and up to two months after completion of antibi-
otic therapy[18]. Several studies have shown that 
probiotics are effective in preventing and treating 
antibiotic-associated diarrhoea, particularly in the 
adult population [1, 3, 18]. Several probiotics have 
been studied in the prevention and treatment of 
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antibiotic-associated diarrhoea (AAD). These include 
Saccharomyces boulardii,which produces a protease 
that destroys the receptor site for Clostridium dif-
ficile toxin A and B, preventing its attachment [1]. In 
C. difficile infections probiotics “aim to restore the 
gut’s colonisation resistanceby providing a barrier 
of relatively low-virulence microorganisms, mainly 
yeasts or Lactobacillus species – that compete with 
C. difficile for essential nutrient, mucosal adherence 
sites and space” [2]. 
Other benefits of individual probiotic strains include 
reducing fever and incidence of rhinorrhoea and du-
ration of cough and the subsequent requirement for 
antibiotic prescription [9]. Certain probiotics have 
been found to inhibit enteropathogenic Escherichia 
coli (EPEC) adherence by inducing the expression 
of an intestinal mucin gene[10]. It has been sug-
gested that probiotics could offer an alternativeto 
the conventional antimicrobials in the treatment and 
prevention of enteric infections [10]. Various stud-
ies have also accessed the effectiveness of probiotic 
combinations such as VSL#3 and SCM-III (L. aci-
dophilus, L. helveticus and Bifidobacterium spp.) in 
the treatment of irritable bowel disease (IBD) [30]. 
Most studies showed that probiotic combinations 
were effective in reducing the severity of IBD symp-
toms, such as abdominal pain, distension, flatulence 
and discomfort [30]. 
A study by Zuccotti et al. found that probiotics could 
be effective alternatives to antibiotic therapy in the 
treatment of urogenital infections in women [23]. 
The use of antibiotics in urogenital infections is of-
ten accompanied by several unwanted side effects, 
such as reducing the general counts of lactobacilli 
causing GI symptoms. Antibiotics are also ineffec-
tive in restoring the urinary tract’s natural barrier 
against infection [6, 23]. According to Reid and 
Bruce , patients are often frustrated with repeatedly 
being prescribed antibiotics, which are becoming 
less effective due to the development of antibiotic 
resistance [22]. The type of antibiotic used and also 
the individual patient’s risk factors are important 
factors that play a role in the incidence of AAD 
and not all antibiotics are equally likely to cause 
AAD [18]. According to Venugopalan et al., due 
to the recent increases in the incidence and sever-
ity of Clostridium difficile infections, particularly in 
hospitalized patients, there is an urgent need for a 
safe and effective alternative to antibiotic therapy 
[7]. Subsequently, clinicians are considering the use 
of probiotics, either alone or in combination with 
antibiotic therapy for the treatment and prevention 
of C. difficile infection [7]. Antibiotics are generally 
effective in reducing the symptoms from C. difficile 
infection, although often the disease frequency re-
lapses since antibiotics also disrupt the microflora of 
the gut [2]. This is one reason why non-antibiotic 
strategies such as probiotics have been investigated 
in the prevention and treatment of C. difficile infec-
tions [2]. 
Summary
In conclusion, considering all the evidence that has 
been given in this review it is clear that there is a 
scientific basis for the use of probiotics in the treat-
ment and prevention of several infectious diseases, 
as an alternative or co-therapy to conventional an-
tibiotic treatments. Probiotics have the benefit of 
being relatively safe in comparison to antibiotics, 
with fewer side effects and they are particularly cost 
effective. Probiotics offer various other additional 
health benefits and, when used alongside antibiot-
ics, can reduce the incidence and severity of a range 
of side-effects normally associated with antibiotic 
therapy. Although there have been several studies 
providing evidence to suggest that probiotics could 
provide an effective alternative to antibiotic therapy 
or even be used alongside antibiotic therapy, more 
up-to-date clinical trials and studies are needed 
to provide conclusive evidence in order to validate 
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these findings. Future research could also focus on 
the possibility of probiotics being prescribed in gen-
eral practice and on educating physicians on the 
role that probiotics have in the prevention and man-
agement of disease. It is apparent that clinical trials 
are needed to assessthe possible consequences of 
AAD, by looking at alternatives such as discontinu-
ing antibiotic therapy, hospitalization or intravenous 
rehydration .
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